At a median planned follow-up of approximately three years, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% (HR=0.510 [95% CI, 0.288-0.906]; one-sided nom… [+68117 chars]Read More
Moderna And Merck Announce mRNA4157 V940 In Combination with KeytrudaR Pembrolizumab Demonstrated Continued Improvement in RecurrenceFree Survival and Distant MetastasisFree Survival in Patients with HighRisk Stage IIIIV Melanoma Moderna Investor Relations
